Taiho Pharmaceutical and Fujifilm Forge Strategic Alliance for Next-Generation ADC Development#Japan#Tokyo#ADC_technology#Fujifilm#Taiho_Pharmaceutical
Taiho Pharmaceutical and Fujifilm Forge Strategic Alliance for Next-Generation ADC Development
Taiho Pharmaceutical and Fujifilm have entered a strategic partnership to enhance the manufacturing process of next-generation antibody-drug conjugates (ADCs).
third-news.com
August 3, 2026 at 4:24 AM
Taiho Pharmaceutical and Fujifilm Forge Strategic Alliance for Next-Generation ADC Development#Japan#Tokyo#ADC_technology#Fujifilm#Taiho_Pharmaceutical
Allink Biotherapeutics Successfully Raises $47 Million in Series A Extension for Clinical Advancement#Shanghai#United_States#Clinical_Trials#Allink_Biotherapeutics#ADC_technology
Allink Biotherapeutics Successfully Raises $47 Million in Series A Extension for Clinical Advancement
Allink Biotherapeutics has completed a $47 million extension round of Series A funding to advance clinical programs and innovative platforms, enhancing their ADC technology development.
third-news.com
December 16, 2025 at 1:58 PM
Allink Biotherapeutics Successfully Raises $47 Million in Series A Extension for Clinical Advancement#Shanghai#United_States#Clinical_Trials#Allink_Biotherapeutics#ADC_technology
Kowa Company Reveals Promising K-679 Antibody-Drug Conjugate with Unmatched Tumor Selectivity and Efficacy#Japan#Nagoya#ADC_technology#K-679#Kowa_Company
Kowa Company Reveals Promising K-679 Antibody-Drug Conjugate with Unmatched Tumor Selectivity and Efficacy
Kowa Company announced the upcoming presentation of K-679, a groundbreaking unimicelle-based antibody-drug conjugate (ADUC) showing remarkable efficacy in preclinical models.
third-news.com
April 6, 2026 at 8:17 AM
Kowa Company Reveals Promising K-679 Antibody-Drug Conjugate with Unmatched Tumor Selectivity and Efficacy#Japan#Nagoya#ADC_technology#K-679#Kowa_Company
CastBio Secures Funding Through Real Tech Fund's J-KISS Options#Japan#Tokyo#ADC_technology#CastBio#Real_Tech_Fund
CastBio Secures Funding Through Real Tech Fund's J-KISS Options
CastBio has successfully raised funds through J-KISS options, focusing on developing innovative cancer treatments using unique technologies.
third-news.com
May 18, 2026 at 12:54 AM
CastBio Secures Funding Through Real Tech Fund's J-KISS Options#Japan#Tokyo#ADC_technology#CastBio#Real_Tech_Fund
Piramal Pharma Solutions Launches Innovative Payload-Linker Suite in Michigan to Enhance Drug Development#USA#ADC_technology#Piramal_Pharma#Riverview#Payload-Linker
Piramal Pharma Solutions Launches Innovative Payload-Linker Suite in Michigan to Enhance Drug Development
Piramal Pharma Solutions has unveiled a cutting-edge payload-linker suite at its Riverview, Michigan site, enhancing capabilities in drug development.
third-news.com
May 14, 2026 at 12:09 AM
Piramal Pharma Solutions Launches Innovative Payload-Linker Suite in Michigan to Enhance Drug Development#USA#ADC_technology#Piramal_Pharma#Riverview#Payload-Linker
CStone Pharmaceuticals Unveils Promising Preclinical Data for Three Innovative ADCs at AACR 2026#China#Suzhou#ADC_technology#CStone_Pharmaceuticals#CS5007#CS5006#CS5008
CStone Pharmaceuticals Unveils Promising Preclinical Data for Three Innovative ADCs at AACR 2026
CStone Pharmaceuticals presents groundbreaking preclinical findings for three advanced ADCs at AACR 2026, promising enhanced treatment options for various cancers.
third-news.com
April 20, 2026 at 12:20 AM
CStone Pharmaceuticals Unveils Promising Preclinical Data for Three Innovative ADCs at AACR 2026#China#Suzhou#ADC_technology#CStone_Pharmaceuticals#CS5007#CS5006#CS5008
Collaboration Between Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Enhances ADC Development and Manufacturing#India#Mumbai#ADC_technology#Piramal_Pharma#Ajinomoto_Bio-Pharma
Collaboration Between Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Enhances ADC Development and Manufacturing
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services announce a strategic collaboration to improve the production and development of antibody-drug conjugates (ADCs).
third-news.com
April 16, 2026 at 8:40 PM
Collaboration Between Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Enhances ADC Development and Manufacturing#India#Mumbai#ADC_technology#Piramal_Pharma#Ajinomoto_Bio-Pharma
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Team Up for ADC Development#India#Mumbai#ADC_technology#Piramal_Pharma#Aji_Bio-Pharma
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Team Up for ADC Development
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services collaborate to enhance antibody-drug conjugate production and development.
third-news.com
April 16, 2026 at 5:19 PM
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Team Up for ADC Development#India#Mumbai#ADC_technology#Piramal_Pharma#Aji_Bio-Pharma
Piramal Pharma Solutions and Ajinomoto Collaborate to Enhance ADC Manufacturing Capabilities#None#ADC_technology#Piramal_Pharma_Solutions#Ajinomoto_Bio-Pharma_Services
Piramal Pharma Solutions and Ajinomoto Collaborate to Enhance ADC Manufacturing Capabilities
Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to boost development and manufacturing in antibody-drug conjugates, leveraging their combined expertise.
third-news.com
April 16, 2026 at 12:35 PM
Piramal Pharma Solutions and Ajinomoto Collaborate to Enhance ADC Manufacturing Capabilities#None#ADC_technology#Piramal_Pharma_Solutions#Ajinomoto_Bio-Pharma_Services
K-679: A Breakthrough in Antibody-Drug Conjugate Technology for Enhanced Tumor Targeting#Japan#Nagoya#ADC_technology#K-679#Kowa_Company
K-679: A Breakthrough in Antibody-Drug Conjugate Technology for Enhanced Tumor Targeting
K-679, an innovative unimicelle-based antibody-drug conjugate, shows selective pharmacokinetics and excellent efficacy in preclinical models, soon to be presented at AACR 2026.
third-news.com
April 6, 2026 at 8:15 AM
K-679: A Breakthrough in Antibody-Drug Conjugate Technology for Enhanced Tumor Targeting#Japan#Nagoya#ADC_technology#K-679#Kowa_Company
WuXi XDC and Earendil Labs Join Forces to Innovate in Antibody-Drug Conjugate Technology#China#Shanghai#ADC_technology#WuXi_XDC#Earendil_Labs
WuXi XDC and Earendil Labs Join Forces to Innovate in Antibody-Drug Conjugate Technology
WuXi XDC collaborates with Earendil Labs, leveraging AI to advance antibody-drug conjugate technology, focusing on treatment for significant medical needs.
third-news.com
February 27, 2026 at 4:22 PM
WuXi XDC and Earendil Labs Join Forces to Innovate in Antibody-Drug Conjugate Technology#China#Shanghai#ADC_technology#WuXi_XDC#Earendil_Labs
Earendil Labs Partners with WuXi XDC to Advance ADC Technology with AI Innovations#United_States#Wilmington#ADC_technology#WuXi_XDC#Earendil_Labs
Earendil Labs Partners with WuXi XDC to Advance ADC Technology with AI Innovations
Earendil Labs collaborates with WuXi XDC to enhance next-generation antibody-drug conjugates using AI-driven technology, aiming for impactful medical advancements.
third-news.com
February 27, 2026 at 3:11 PM
Earendil Labs Partners with WuXi XDC to Advance ADC Technology with AI Innovations#United_States#Wilmington#ADC_technology#WuXi_XDC#Earendil_Labs
Ajinomoto Bio-Pharma Services Recognized at World ADC Awards for Innovative AJICAP Technology#USA#Tokyo#ADC_technology#Ajinomoto#Bio-Pharma
Ajinomoto Bio-Pharma Services Recognized at World ADC Awards for Innovative AJICAP Technology
Ajinomoto Bio-Pharma Services has achieved recognition for its AJICAP technology at the World ADC Awards, highlighting advancements in biopharmaceutical development.
third-news.com
November 17, 2025 at 3:03 PM
Ajinomoto Bio-Pharma Services Recognized at World ADC Awards for Innovative AJICAP Technology#USA#Tokyo#ADC_technology#Ajinomoto#Bio-Pharma
Mycenax and RIN Collaboration to Enhance ADC Development Through Innovative Licensing Deal#Taiwan#Taipei#ADC_technology#Mycenax#Rin
Mycenax and RIN Collaboration to Enhance ADC Development Through Innovative Licensing Deal
Mycenax Biotech Inc. and RIN Institute forge a licensing agreement to advance antibody-drug conjugate technology, enhancing global drug solutions.
third-news.com
October 31, 2025 at 7:06 AM
Mycenax and RIN Collaboration to Enhance ADC Development Through Innovative Licensing Deal#Taiwan#Taipei#ADC_technology#Mycenax#Rin
Tagworks Pharmaceuticals Launches Third Dose Phase 1 Trial of TGW101 for Solid Tumors#Netherlands#ADC_technology#Nijmegen#Tagworks#TGW101
Tagworks Pharmaceuticals Launches Third Dose Phase 1 Trial of TGW101 for Solid Tumors
Tagworks Pharmaceuticals has initiated the third dose of its Phase 1 clinical trial for TGW101, an innovative treatment for advanced solid tumors, showcasing its commitment to pioneering cancer therapies.
third-news.com
September 10, 2025 at 7:47 PM
Tagworks Pharmaceuticals Launches Third Dose Phase 1 Trial of TGW101 for Solid Tumors#Netherlands#ADC_technology#Nijmegen#Tagworks#TGW101
Acepodia Unveils Promising Preclinical Findings for Innovative Antibody-Drug Conjugate Technology#USA#Chicago#Cancer_Research#ADC_technology#Acepodia
Acepodia Unveils Promising Preclinical Findings for Innovative Antibody-Drug Conjugate Technology
Acepodia presents exciting preclinical results for their dual-payload antibody-drug conjugate technology at the AACR Annual Meeting 2025. This innovation showcases significant potential in cancer treatment.
third-news.com
April 21, 2025 at 11:07 AM
Acepodia Unveils Promising Preclinical Findings for Innovative Antibody-Drug Conjugate Technology#USA#Chicago#Cancer_Research#ADC_technology#Acepodia
WuXi XDC and AbTis Forge Strategic Alliance for Future ADC Advances#China#Shanghai#ADC_technology#WuXi_XDC#AbTis
WuXi XDC and AbTis Forge Strategic Alliance for Future ADC Advances
WuXi XDC partners with AbTis to enhance next-generation ADCs through innovative technology integration, accelerating development in bioconjugates.
third-news.com
March 11, 2025 at 2:10 PM
WuXi XDC and AbTis Forge Strategic Alliance for Future ADC Advances#China#Shanghai#ADC_technology#WuXi_XDC#AbTis
Boehringer Ingelheim Expands Cancer Treatment Portfolio through Synaffix Licensing Deal#Germany#Boehringer_Ingelheim#ADC_technology#Synaffix#Ingelheim
Boehringer Ingelheim Expands Cancer Treatment Portfolio through Synaffix Licensing Deal
Boehringer Ingelheim boosts its oncology portfolio by licensing innovative ADC technology from Synaffix, aiming to enhance cancer treatment outcomes.
third-news.com
January 9, 2025 at 1:14 PM
Boehringer Ingelheim Expands Cancer Treatment Portfolio through Synaffix Licensing Deal#Germany#Boehringer_Ingelheim#ADC_technology#Synaffix#Ingelheim
Elevation Oncology Collaborates with Synaffix to Enhance ADC Drug Development#Netherlands#Amsterdam#ADC_technology#Synaffix#Elevation_Oncology
Elevation Oncology Collaborates with Synaffix to Enhance ADC Drug Development
Elevation Oncology has secured a licensing agreement with Synaffix for innovative ADC technology to boost their drug development pipeline targeting solid tumors.
third-news.com
December 12, 2024 at 12:33 PM
Elevation Oncology Collaborates with Synaffix to Enhance ADC Drug Development#Netherlands#Amsterdam#ADC_technology#Synaffix#Elevation_Oncology
Allink Biotherapeutics Secures $42M to Enhance Bispecific Antibody and ADC Development#USA#Beijing#Allink_Biotherapeutics#Lanchi_Ventures#ADC_technology
Allink Biotherapeutics Secures $42M to Enhance Bispecific Antibody and ADC Development
Allink Biotherapeutics has successfully raised $42 million in Series A funding to further develop bispecific antibodies and ADCs in global markets.
third-news.com
November 28, 2024 at 1:36 PM
Allink Biotherapeutics Secures $42M to Enhance Bispecific Antibody and ADC Development#USA#Beijing#Allink_Biotherapeutics#Lanchi_Ventures#ADC_technology